FOR IMMEDIATE RELEASE
Hawthorne, CA, November 9, 2015 – BioDiscovery, Inc., a leader in innovative genomic data analysis software solutions for life sciences research and clinical applications, announced today that Ann & Robert H. Lurie Children’s Hospital of Chicago (formally Children’s Memorial Hospital) has licensed BioDiscovery’s NxClinical software, an innovative new solution for genetic data analysis and management for clinical labs.
Lurie Children’s Hospital is one of the top pediatric providers in the Midwest and as the pediatric teaching facility of Northwestern University Feinberg School of Medicine is also a recognized leader in research and education. Lurie Children’s Hospital has been a long time customer of BioDiscovery and has recently transitioned to using NxClinical software.
“The functionality of NxClinical has allowed us to simplify and standardize our interpretation of CNVs across our group of Directors. This significantly reduces the time required to review the 10+ variants identified per genome,” said Lawrence Jennings, MD, PhD, Director, HLA and Molecular Diagnostic Labs. The genetics labs at Lurie Children’s Hospital offers cytogenetic and molecular testing for diagnosis of inherited disorders and also offers testing for transplantation.
BioDiscovery’s NxClinical software increases accuracy and efficiency in molecular genetics and cytogenomics labs’ workflows. It is a multi-user system with a central database, automated and standardized processes, and integrated reference databases to provide robust and rapid interpretation and reporting of genomic variations.
NxClinical’s hallmark, platform-independence, allows labs to use the same software for analysis and interpretation of data from various manufacturers allowing much greater flexibility and ease in changing vendors or technologies without having to invest additional time and money in installation, training, and validation with a new system. The automated workflow can be customized to mirror a lab’s decision making process and classification terms to pre-classify events, removing repetitive tasks and minimizing potential human error. The system allows enforcement of lab SOPs with assigned user roles and privileges for appropriate user access, extensive audit trail capabilities, and flexible deployment with local or cloud-based options.
About BioDiscovery, Inc.
BioDiscovery, Inc. is dedicated to the development of state-of-the-art software products for life science research as well as clinical applications. The company’s mission is to enable scientists to eliminate disease and suffering through application of computational technologies and translating these findings directly and rapidly to clinical use. From its inception in 1997, BioDiscovery has been an innovative leader in the genomics field having introduced the first dedicated commercial software tool for analyzing microarray images. Since then, innovation has continued to be a top priority. BioDiscovery’s passion to make a difference has further extended the company’s reach into creating the most comprehensive enterprise-wide system enabling research findings to translate into clinical applications and make direct impact on patient care. For more information, visit http://www.biodiscovery.com.
The BioDiscovery software tools referenced are designed to assist clinicians and are not intended as primary diagnostic tools. It is each lab’s responsibility to use the software in accordance with internal policies as well as in compliance with applicable regulations.